anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:The titled cellular surface antigen recognition type antibody, produced by a hybridoma prepared by using a cellular strain (MKN-45) derived from a gastric low differentiation type gladular cancer as an immunization source, having a light chain of IgG1(K) and capable of exhibiting positive reaction to cancer cells, e.g. specific gastric cancer or esophageal cancer. CONSTITUTION:A monoclonal antibody obtained by fractionating a cell extract of an established cell (MKN-45) derived from a gastric low differentiation type glandular cancer, mixing the resultant high-molecular fraction having 700,000-1,500,000mol.wt. with complete Freund&#39;s adjuvant, immunizing an animal, e.g. mouse, with the resultant mixture, collecting a cell producing an antibody, carrying out cell fusion with a myelomatous cell of an animal of the same species, cloning the resultant cell to give a cloned hybridoma, transplanting the resultant cloned hybridoma to the abdominal cavity of an animal, e.g. BALB/C mouse, to produce the aimed antibody capable of exhibiting positive reaction to cancer cells of gastric cancer (MKN-45 or KATO-III), esophageal cancer (TE-3), lung cancer (PC-10) and colonic cancer (Colo201) and recovering and purifying the antibody from the ascites.
PROBLEM TO BE SOLVED: To obtain a makeup cosmetic overcoming defects of usual cosmetics peculiarly appearing under a light source for photographing such as loss of brightness or a trace of fixing of makeup. SOLUTION: This solid makeup cosmetic for bodies contains 30-40 wt.% of a powder. In the solid makeup cosmetic, the powder is only one or more kinds selected from titanium dioxide, yellow iron oxide, red iron oxide, prussian blue, ultramarine, chromium oxide, chromium hydroxide, Red No. 201, Red No. 202, Red No. 226, Yellow No. 4 lake, Yellow No. 401, Blue No. 404 and silica-titanium sericite-silica multilayered coating powder which may be doped with other metal atoms. The cosmetic further contains 10-15 wt.% of dimethicone and 5-10 wt.% of a polyethylene having &gt;=20 and &lt;=30 average degree of polymerization.
1516525 Anhydrous compositions for remineralizing tooth enamel PROCTER &amp; GAMBLE CO 9 Oct 1975 [10 Oct 1974] 41435/75 Heading A5B Anhydrous compositions for the remineralizing of demineralized dental enamel e.g. dentifrices, mouthwashes, toothpastes, chewing gums and dental prophylaxis pastes comprise (A) a water-soluble calcium salt e.g. calcium chloride, acetate, formate, lactate or nitrate; (B) a water-soluble phosphate salt e.g. disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, trisodium phosphate and anhydrous phosphoric acid; (C) the balance, anhydrous ingredients for use in the oral cavity; wherein the molar ratio of calcium to phosphate is from 0.01:1 to 100:1, and the composition, when dispersed in water at a concentration of 1 part by weight of composition to 2 parts by weight of water, produces a pH of from 2 to 5. Additional ingredients include a watersoluble salt of magnesium or a heavy metal such as manganese, tin, zinc, indium, aluminium, zirconium, iron, titanium, vanadium and the rare earth metals e.g. lanthanum and cerium; a water soluble salt of an anion capable of forming a water-insoluble precipitate with the cations of calcium, magnesium or the above specified heavy metals e.g. fluoride; and other conventional dentifrice components.
[GB1516525A]
FIELD: medicine.SUBSTANCE: invention refers to medicine and can be used for the correction of gynoid obesity. That is ensured by typing an eating disorder to be psychologically corrected. A diet therapy is prescribed with a caloric value determined by reducing a patient&#39;s habitual daily average caloric requirement per a percent equal to the patient&#39;s body weight index. That is combined with a low-carbohydrate diet with the carbohydrate content reduced to 40-60 g/day for 2 weeks. That is followed by prescribing a low-fat diet with the fat content reduced to 40-60 g/day for 10 weeks with avoiding fast assimilated carbohydrates having a glycaemic index of more than 50. The diet therapy cycle is repeated. That is combined with graduated aerobic physical exercises with no weight and resistance for the muscle groups of the lower body. There are also performed muscle-strengthening load exercises for the muscle group of the upper body promoting muscle fatigue. Between and after the graduated physical exercises, there are performed prolonged aerobic physical loads at least 5 days a week for 40-60 minutes. That is combined with the drug-free procedures aiming at improving the regional blood flow, increasing gluteofemoral and lower extremities muscle tonus. The low-fat diet involves administering health aids from the group of intestinal membrane-bound alpha-glucosidase and pancreatic alpha-amylase inhibitors. The course of the obesity correction involves administering catechin-containing preparations or biologically active additives. From the second month from the beginning of the obesity correction, the patient&#39;s face is exposed to full-spectrum natural or artificial light at intensity of not less than 2,000 lux for 1-2 hours a day simultaneously or alternatively with the physical loads.EFFECT: method provides the effective weight reduction in the patients with gynoid obesity with reducing side effects.5 cl, 8 tbl, 2 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a novel allergen protein associated with cedar pollen allergy other than Cry j 1 and Cry j 2, and diagnostic, preventive and therapeutic agents for the allergy using the protein.  &lt;P&gt;SOLUTION: Cedar pollen allergen protein CPA9 contained in the cedar pollen is found wherein the protein exhibits a molecular weight of 70-110 kDa when measured by SDS-polyacrylamide gel electrophoresis, and an isoelectric point of about 6.0-8.0 when measured by isoelectric electrophoresis. The partial amino acid sequence of the protein is also clarified by mass spectrometry. Further, a cDNA sequence encoding the CPA9 protein and the total amino acid sequence of the CPA9 protein are demonstrated. It is revealed that the CPA9 protein is a novel cedar pollen allergy protein having novel immunological characteristics different from the known allergens Cry j 1 and Cry j 2 by exhibiting the frequency of reaction of a natural CPA9 and recombinant CPA9 with the serum of a patient with cedar pollen allergy.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain a dentifrice composition capable of foaming by brushing and brushing teeth for a long period without dripping the foam from a mouth even when brushing the teeth for the long period due to a slight reduction in viscosity of the foam even when diluted with saliva. SOLUTION: This dentifrice composition contains 0.5-20 wt.% of a surfactant, e.g. a fatty acid ester of a sugar (alcohol), 1-3 wt.% of a binder, e.g. xanthan gum, 10-70 wt.% of a humectant, e.g. glycerol, 5-70 wt.% of a polishing agent, e.g. calcium secondary phosphate dihydrate and 10-50 wt.% of water and is capable of foaming by brushing and causing a slight reduction in viscosity of the foam even when diluted with saliva. The value of complex modulus of elasticity G* obtained by a dynamic viscoelastic measurement of the foam produced by brushing is &gt;=300 dyne/cm2, preferably 300-600 dyne/cm2 and the value of dynamic loss tangent tanδ is preferably 0.5-1.5.
PURPOSE:To obtain the titled substance easily without varying the composition of the phospholipid and to expand the utility range of the substance in pharmaceutical field, by dissolving a refined phospholipid containing lysophosphatidylcholine in a chlorine-containing solvent and contacting the solution with silica gel. CONSTITUTION:A refined phospholipid containing lysophosphatidylcholine is dissolved in a chlorine-containing solvent (preferably a solvent having a boiling point of &lt;=100 deg.C, e.g. dichloromethane) and the solution is made to contact with silica gel usually by adding silica gel to the solution and stirring the mixture to form a suspension. The silica gel is removed from the suspension e.g. by filtration and the chlorine-containing solvent is distilled off from the solution e.g. by vacuum distillation to obtain the objective substance. The refined phospholipid raw material is produced e.g. by extracting fish roe with ether, etc., and treating the resultant crude animal phospholipid with acetone to remove neutral lipid therefrom.
PURPOSE: To provide an alcoholic irritating odor masking agent capable of supporting the irritating odor by alcohol in a cosmetic, a drink, a food and a perfume containing alcohol, by consisting the masking agent of an ester represent by a general formula such as methyl acetate, ethyl acetate or isoamyl acetate. CONSTITUTION: This alcoholic irritating odor masking agent consists of an ester represented by a general formula such as methyl acetate, ethyl acetate or isoamyl acetate (R1 and R2 each represents a short chain alkyl group allowed to be independently branched). The above alcohol is ethanol. Either one kind selected from these esters or a mixture of &gt;=2 kinds can be used as the masking agent. The concentration of the masking agent capable of effectively exhibiting the action is 0.1-10wt.%, more preferably 0.5-5wt.% based on the alcohol in a case via the sense of smell such as in perfumes, etc. The action is remarkable and physical properties of lower alcohols such as solubility are not damaged. In a case via both senses of smell and taste such as in drinks or foods, a concentration of 0.01-2000ppm is preferable.
NEW MATERIAL:The 2,3-dihydro-indene derivative of formula I (n is 2-4; R&lt;1&gt; and R&lt;2&gt; are H, halogen, nitro, lower alkyl or lower alkyloxy; provided that R&lt;1&gt; and R&lt;2&gt; are not H at the same time). EXAMPLE:6-Fluoro-1-oxo-2,3-dihydro-2-indenebutyric acid. USE:Pharmaceuticals. It has low toxicity, and antiallergic activity to anaphylactic, cytotoxic and Arthus allergies. Especially exhibiting strong pharmacological activity to Arthus allergy, and useful as a preventive and remedy for allergic inflammation such as renal diseases, rheumatism, collagen disease, autoimmune diseases, etc. It has blood platelet coagulation inhibiting activity, etc. PROCESS:The compound of formula I can be prepared, e.g. by reacting the compound of formula II (R&lt;3&gt; is H, lower alkoxy, etc.) with the alkylating agent of formula III (X is halogen; Y is cyano or lower alkoxycarbonyl) in the presence of an alkali and an organic amine in a solvent, and hydrolyzing the reaction product with a mineral acid.
The invention comprises compounds of general formula &lt;FORM:0938201/IV(a)/1&gt; wherein A stands for the ethylene radical or an ethylene radical containing a C1-4-alkyl substituent and the broken lines denote optional bonds, and acid addition salts; and their preparation by dehydrating a hydroxy compound of formula &lt;FORM:0938201/IV(a)/2&gt; &lt;FORM:0938201/IV(a)/3&gt; in an organic solvent in the presence of a dehydrating agent or by reacting a halogen-alkylidene compound of formula &lt;FORM:0938201/IV(a)/4&gt; with benzylamine or a C1-4-alkylamine.  Separation of stereoisomeric halogen-substituted compounds is mentioned.  Hydroxy compounds of the second general formula above may be prepared by (1) reacting an appropriate 5-keto compound with an N-alkyl-N-benzyl-aminoalkyl halide as magnesium, lithium or zinc metal derivative followed by hydrolysis and debenzylation by hydrogenolysis of the resulting 5-hydroxy-5-(N-alkyl-N-benzyl)aminoalkyl compound; (2) reacting an appropriate 5-keto compound with a compound of formula &lt;FORM:0938201/IV(a)/5&gt; followed by hydrolysis and then by hydrogenation of the triple bond of the resulting 5-hydroxy- 5-(N- alkyl- N-benzyl)amino-alkynyl compound to form a 5-hydroxy-5-JN-alkyl- N-benzyl)- aminoalkyl compound which can be debenzylated by hydrogenolysis; (3) reacting an appropriate 5-keto compound with an ethyl magnesium halide, dehydrating the resulting carbinol and oxidising the consequent ethylidene group to the 5-acetyl compound which is reacted with an appropriate amine and aldehyde and then catalytically reduced.  Halogeno-alkylidene compounds of the third general formula above are prepared by the following steps; (1) reacting an appropriate 5-keto compound with an etherified hydroxy-propyl halide or a propenyl halide as organo-magnesium derivative, to form on hydrolysis the corresponding 5-hydroxy-5-substituted compound which is then subjected to simultaneous dehydration and halogenation e.g. with hydrobromic acid or phosphorus oxychloride. p  1-Chloro-2-methyl- 3-(N-methyl- N-benzyl)-aminopropane is prepared from the corresponding 3-bromopropane and amine.  Compositions having activity on the central nervous system comprise a compound or salt of the invention in association with a compatible pharmaceutical carrier.  Enteral and parenteral administration of solid (tablets, capsules, dragees, suppositories) and liquid (solutions, suspensions, emulsions) preparations is mentioned.
NEW MATERIAL:The compound of formula (X is lower alkyl, lower alkoxy, nitro or halogen; n is 1 or 2). EXAMPLE:1-(2&#39;-Methoxyphenoxycarbonyl)-2-pyrrolidinone. USE:A nootropic agent. It is effective e.g. in promoting the learning activity, increasing the resistance of brain against the stress such as anoxia and promoting the cerebral metabolism of especially senile patient. PREPARATION:The objective compound of formula can be produced by chloroformylating phenol or a substituted phenol with phosgene in the presence of an acid acceptor (e.g. pyridine) in a solvent such as benzene and reacting the resultant corresponding chloroformylated phenol or substituted phenol with 2-pyrrolidinone or a reactive derivative of 2-pyrrolidinone in the presence of an acid acceptor.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a modified aluminum powder stable to the change in hue, or the like, caused by contact with water and passage of time, having excellent dispersibility in an oil component for cosmetics, metallic luster, or the like, and useful as a pigment for the cosmetics; and to prepare a stable cosmetic having excellent characteristics, usability, sense of use, or the like, by formulating the pigment for the cosmetics comprising the modified aluminum powder.  &lt;P&gt;SOLUTION: The pigment for the cosmetics comprises the aluminum powder the surface of which is covered with a resin. The pigment for the cosmetics can be the aluminum powder the surface of which is covered with the resin obtained by polymerizing a polymerizable monomer or oligomer in a solvent dispersion of the aluminum powder. A pigment composition for the cosmetics comprises the pigment for the cosmetics and the oil component for the cosmetics. The pigment for the cosmetics and the pigment composition for the cosmetics are formulated with the cosmetics exemplified by a makeup cosmetic.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
Provided are compositions and methods of treating impaired glucose tolerance which substantially increase the islet donor pool and safety as well as remove the need for anti-rejections drugs. Described are methods of making cell clusters comprising: expanding pancreatic islet cells; and forming cell clusters comprising: the expanded islet cells and mesenchymal/adipose stem cells. Expansion of the islet cells may include=&gt;five population doublings. The islet cells may be primary islet cells obtained from an adult, non-diabetic donor having a North America Islet Donor Score (NAIDS) of &lt;80. Described are cell clusters produced by the methods. Additionally, methods of treatment by intraperitoneal administration of islet-sized cell clusters composed of high numbers of mesenchymal stem cells and expanded pancreatic islet cells, durably and reversibly treats, without hypoglycemia, both streptozotocin-induced and spontaneous Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, and other types of insulin-dependent diabetes mellitus, or impaired glucose tolerance.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to oncology, and can be used to predict the status of the epidermal growth factor receptor Her2/neu in a primary tumour in patients with breast cancer. At the stage of diagnostics morphological and immunohistochemical examination with determination of histological type of breast cancer and its molecular characteristics are performed after sampling of biopsy material. Thereafter, 2 hours after administration of the preparation &#34;99mTc - DARPin9_29&#34;, single-photon emission computed tomography (SPECT) of the chest is performed, at which the labelled protein accumulation is assessed in the breast tumour and the symmetrical section of the opposite breast (background) and the tumour/background ratio is determined. Value of the regression equation Y is calculated by the formula: Y = -85.93 + 56.69 * X1, where -85.93 is the value of the regression coefficient of the free member; X1 is the tumour/background ratio in 2 hours after administration of the preparation &#34;99mTc-DARPin9_29&#34;; X1 = 1 with tumour/background ratio less than or equal to 7.95; X1 = 2 with a tumour/background ratio of more than 7.95; 56.69 is the value of the regression coefficient of this feature. Probability P is determined by formula: P = eY/ (1 + eY), where is a mathematical constant equal to 2.72. If P is more than or equal to 50%, a high probability of the Her2-positive tissue status of the primary tumour node is predicted, while P is less than 50%.EFFECT: method enables accurate and informative prediction of the Her2/neu epidermal growth factor receptor status in primary tumours in patients with breast cancer due to a complex of studies: morphological, immunohistochemical and radiobiological, in which accumulation of preparation &#34;99mTc - DARPin9_29&#34; in breast tumour is assessed by SPECT of chest organs.1 cl, 2 dwg, 3 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a medicine, food, nutrient, healthy product or cosmetic composition prepared from a graphitized cylindrical carbon compound, and to provide a method for producing the graphitized cylindrical carbon compound.  &lt;P&gt;SOLUTION: This graphitized cylindrical carbon compound is produced by subjecting a carbon source to a catalylic reation with a catalyst. The composition of the present invention contains the graphitized cylindrical carbon compound in an amount of ≤50 wt.%. The graphitized cylindrical carbon compound holds DNA molecules, amino acid molecules, polysaccharide molecules, sugars, and Ag ion, Au ion, Pt ion, Rh ion, Fe ion, and the like through functional groups. The active ingredient-holding graphitized cylindrical carbon compounds can be used as raw materials for chemicals, nutrients, healthy products or cosmetic compositions. The composition of the present invention can effectively adsorb/release large amounts of nutrients or stains.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to cosmetics, particularly antiperspirants. An &#34;water-in-oil&#34; emulsion composition of a solid astringent stick contains an antiperspirant salt 34 wt % to 70 wt %, a dispersed water phase containing 15 to 30 wt % of water-soluble astringent antiperspirant aluminium-zirconium salts, 29 wt % to 65 wt % of an oil phase containing at least one oil and hydrocarbon wax which hardens oil; hydrocarbon wax contains at least 1 portion wt/wt of polyethylene of intermediate molecular weight representing average molecular weight making 360 to 460 Da per 8 portions of the oil phase, and 0.125 wt % to 2.0 wt % of a silicone emulsifier. A method for producing the composition and application shows weak or improved braking and weak or improved visible traces. A non-therapeutic method of local sweating inhibition or regulation is provided by rubbing-in, preferentially in an axillary crease. ^ EFFECT: invention provides the required aesthetic characteristics including weak braking and good sliding and subtle traces with preferable hardness of the stick. ^ 26 cl, 11 tbl, 48 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To realize a medical image information management system which can transfer data from a DB1 to a DB2 even during the normal operation of an image server.  &lt;P&gt;SOLUTION: This medical image information management system is equipped with the image server, a storage section, and an image viewer. In this case, the image server has a database section which stores the management information of image data which has been acquired by a photographing apparatus. The storage section is connected with a network, and at the same time, is managed by the image server, and stores the image data. The image viewer is connected with the network, and displays the image of the image data which is stored in the storage section. In the medical image information management system, when the image server is replaced with a new image server, the new image server and a shifting tool are connected with the computer network. Then, the data having been managed by the image server is shifted to the database of the new image server conforming to the command of the shifting tool.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
1,157,741. Preparation of aminomethylenemalononitrile. F. HOFFMANN-LA ROCHE &amp; CO. A.G. 21 Sept., 1966 [24 Sept., 1965], No. 42125/66. Heading C2C. Aminomethylene-malononitrile is obtained by condensing formamidine or a salt thereof with malononitrile. The reaction is suitably effected in the presence of a weak base condensing agent and an inert organic solvent, preferably an alcohol, at 10-30 C., and the formamidine salt employed as starting material may be a salt with a mineral or organic acid. The reaction may also be effected by reacting a formamidine salt with a cation-exchange resin and treating the resulting formamidine resin salt with malononitrile thereby condensing the formamidine with the malononitrile and removing the condensate from the resin; the resinous material employed as the cation-exchange resin suitably contains acidic groups such as sulphonic groups and any insoluble sulphonated polymerizate of a poly-vinyl-aryl compound may be used. The resin employed is preferably of the styrene- (divinyl-benzene) type characterized by the presence of sulphonic acid groups.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a medicine useful for preventing and treating an immunological disease and to provide a method.  &lt;P&gt;SOLUTION: The new gene of an immune function inhibitory molecule participates in modulation of an immune function. The protein is obtained. The method for efficiently evaluating an active modulator against the protein is provided. The new gene (mcd054) of the immune function inhibitory molecule participates in the modulation of the immune function. The protein (MCD054) is encoded by the gene. The recombinant vector contains the DNA. The transformant cell is transformed by the recombinant vector. The method for searching an activity modulation substance of the protein is provided. The antibody has reactivity to the protein or its partial peptide.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
A method for increasing the effectiveness of an anti-fungal compound is described. In the method, an anti-fungal compound and an N-alkyl heterocyclic compound or a salt thereof are administered to a mammal in a combined amount effective to treat a fungal infection. The N-alkyl heterocyclic compound or salt thereof is present in an amount effective to potentiate or increase the anti-fungal activity of the anti-fungal compound. The N-alkyl heterocyclic compound has formula (I). The variable &#34;n&#34; ranges from 5 to 17, and the heterocyclic ring defined by formula (a) is a substituted or unsubstituted ring having four to eight members. A pharmaceutical composition is described where the anti-fungal compound and the N-alkyl heterocyclic compound or salt thereof are present in a combined amount effective to treat a fungal infection. A method for controlling the growth of fungal organisms on various substrates to be inserted into the body using a combined amount of an anti-fungal compound and an N-alkyl heterocyclic compound or a salt thereof is also described.